Iovance Biotherapeutics Reports Q2 2026 Financial Results

What Happened
Iovance Biotherapeutics, Inc. (IOVA) announced its financial results for the quarter ended June 30, 2026 via a press release dated August 6, 2026. The company furnished that press release as Exhibit 99.1 to Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The filing provides the company’s quarterly earnings and a corporate update; the press release itself contains the detailed revenue, expense and operational figures.

Key Details

• Filing date: August 6, 2026 (Form 8-K furnished under Item 2.02).
• Quarter covered: Quarter ended June 30, 2026 (Q2 2026).
• Exhibit furnished: Press release dated August 6, 2026 (Exhibit 99.1).
• Interactive XBRL cover page provided as Exhibit 104.

Why It Matters
This 8-K is the company’s official disclosure of its latest quarterly results and operational update—important for investors tracking Iovance’s earnings, revenue and cash position. Because the press release is furnished (not the full periodic report), investors should review the Exhibit 99.1 press release and subsequent 10-Q for the complete financial statements, metrics and management commentary to assess revenue trends, R&D spending, and cash runway. No executive changes, mergers, or other material events were reported in this filing.